Natalie McCormick1, Mark J O'Connor2, Chio Yokose3, Tony R Merriman4, David B Mount5, Aaron Leong6, Hyon K Choi1. 1. Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, and Arthritis Research Canada, Richmond, British Columbia, Canada. 2. Massachusetts General Hospital, Boston. 3. Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 4. University of Otago, Dunedin, New Zealand, and University of Alabama at Birmingham. 5. Brigham and Women's Hospital, VA Boston Healthcare System, and Harvard Medical School, Boston, Massachusetts. 6. Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, and Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Abstract
OBJECTIVE: Hyperuricemia is closely associated with insulin resistance syndrome (and its many cardiometabolic sequelae); however, whether they are causally related has long been debated. We undertook this study to investigate the potential causal nature and direction between insulin resistance and hyperuricemia, along with gout, by using bidirectional Mendelian randomization (MR) analyses. METHODS: We used genome-wide association data (n = 288,649 for serum urate [SU] concentration; n = 763,813 for gout risk; n = 153,525 for fasting insulin) to select genetic instruments for 2-sample MR analyses, using multiple MR methods to address potential pleiotropic associations. We then used individual-level, electronic medical record-linked data from the UK Biobank (n = 360,453 persons of European ancestry) to replicate our analyses via single-sample MR analysis. RESULTS: Genetically determined SU levels, whether inferred from a polygenic score or strong individual loci, were not associated with fasting insulin concentrations. In contrast, genetically determined fasting insulin concentrations were positively associated with SU levels (0.37 mg/dl per log-unit increase in fasting insulin [95% confidence interval (95% CI) 0.15, 0.58]; P = 0.001). This persisted in outlier-corrected (β = 0.56 mg/dl [95% CI 0.45, 0.67]) and multivariable MR analyses adjusted for BMI (β = 0.69 mg/dl [95% CI 0.53, 0.85]) (P < 0.001 for both). Polygenic scores for fasting insulin were also positively associated with SU level among individuals in the UK Biobank (P < 0.001). Findings for gout risk were bidirectionally consistent with those for SU level. CONCLUSION: These findings provide evidence to clarify core questions about the close association between hyperuricemia and insulin resistance syndrome: hyperinsulinemia leads to hyperuricemia but not the other way around. Reducing insulin resistance could lower the SU level and gout risk, whereas lowering the SU level (e.g., allopurinol treatment) is unlikely to mitigate insulin resistance and its cardiometabolic sequelae.
OBJECTIVE: Hyperuricemia is closely associated with insulin resistance syndrome (and its many cardiometabolic sequelae); however, whether they are causally related has long been debated. We undertook this study to investigate the potential causal nature and direction between insulin resistance and hyperuricemia, along with gout, by using bidirectional Mendelian randomization (MR) analyses. METHODS: We used genome-wide association data (n = 288,649 for serum urate [SU] concentration; n = 763,813 for gout risk; n = 153,525 for fasting insulin) to select genetic instruments for 2-sample MR analyses, using multiple MR methods to address potential pleiotropic associations. We then used individual-level, electronic medical record-linked data from the UK Biobank (n = 360,453 persons of European ancestry) to replicate our analyses via single-sample MR analysis. RESULTS: Genetically determined SU levels, whether inferred from a polygenic score or strong individual loci, were not associated with fasting insulin concentrations. In contrast, genetically determined fasting insulin concentrations were positively associated with SU levels (0.37 mg/dl per log-unit increase in fasting insulin [95% confidence interval (95% CI) 0.15, 0.58]; P = 0.001). This persisted in outlier-corrected (β = 0.56 mg/dl [95% CI 0.45, 0.67]) and multivariable MR analyses adjusted for BMI (β = 0.69 mg/dl [95% CI 0.53, 0.85]) (P < 0.001 for both). Polygenic scores for fasting insulin were also positively associated with SU level among individuals in the UK Biobank (P < 0.001). Findings for gout risk were bidirectionally consistent with those for SU level. CONCLUSION: These findings provide evidence to clarify core questions about the close association between hyperuricemia and insulin resistance syndrome: hyperinsulinemia leads to hyperuricemia but not the other way around. Reducing insulin resistance could lower the SU level and gout risk, whereas lowering the SU level (e.g., allopurinol treatment) is unlikely to mitigate insulin resistance and its cardiometabolic sequelae.
Authors: Loic Yengo; Julia Sidorenko; Kathryn E Kemper; Zhili Zheng; Andrew R Wood; Michael N Weedon; Timothy M Frayling; Joel Hirschhorn; Jian Yang; Peter M Visscher Journal: Hum Mol Genet Date: 2018-10-15 Impact factor: 6.150
Authors: Saeid Safiri; Ali-Asghar Kolahi; Marita Cross; Kristin Carson-Chahhoud; Damian Hoy; Amir Almasi-Hashiani; Mahdi Sepidarkish; Ahad Ashrafi-Asgarabad; Maziar Moradi-Lakeh; Mohammad Ali Mansournia; Jay S Kaufman; Gary Collins; Anthony D Woolf; Lyn March; Emma Smith Journal: Arthritis Rheumatol Date: 2020-09-10 Impact factor: 10.995
Authors: E Muscelli; A Natali; S Bianchi; R Bigazzi; A Q Galvan; A M Sironi; S Frascerra; D Ciociaro; E Ferrannini Journal: Am J Hypertens Date: 1996-08 Impact factor: 2.689
Authors: Adam G Tabák; Markus Jokela; Tasnime N Akbaraly; Eric J Brunner; Mika Kivimäki; Daniel R Witte Journal: Lancet Date: 2009-06-08 Impact factor: 79.321
Authors: Claudia Langenberg; Nicholas J Wareham; Robert A Scott; Tove Fall; Dorota Pasko; Adam Barker; Stephen J Sharp; Larraitz Arriola; Beverley Balkau; Aurelio Barricarte; Inês Barroso; Heiner Boeing; Françoise Clavel-Chapelon; Francesca L Crowe; Jacqueline M Dekker; Guy Fagherazzi; Ele Ferrannini; Nita G Forouhi; Paul W Franks; Diana Gavrila; Vilmantas Giedraitis; Sara Grioni; Leif C Groop; Rudolf Kaaks; Timothy J Key; Tilman Kühn; Luca A Lotta; Peter M Nilsson; Kim Overvad; Domenico Palli; Salvatore Panico; J Ramón Quirós; Olov Rolandsson; Nina Roswall; Carlotta Sacerdote; Núria Sala; María-José Sánchez; Matthias B Schulze; Afshan Siddiq; Nadia Slimani; Ivonne Sluijs; Annemieke Mw Spijkerman; Anne Tjonneland; Rosario Tumino; Daphne L van der A; Hanieh Yaghootkar; Mark I McCarthy; Robert K Semple; Elio Riboli; Mark Walker; Erik Ingelsson; Tim M Frayling; David B Savage Journal: Diabetes Date: 2014-06-19 Impact factor: 9.461